Pyxis Oncology Stock (NASDAQ:PYXS)
Previous Close
$1.54
52W Range
$1.49 - $6.85
50D Avg
$2.99
200D Avg
$3.71
Market Cap
$100.50M
Avg Vol (3M)
$1.22M
Beta
1.28
Div Yield
-
PYXS Company Profile
Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors. The company's antibody drug conjugate (ADC) product candidates comprise of PYX-201, an investigational novel ADC to treat NSCLC, breast cancer, and other solid tumors; PYX-202, an investigational novel ADC for treatment of SCLC, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational ADC for the treatment of acute myeloid leukemia and myeloid dysplastic syndrome. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
PYXS Performance
Peer Comparison
Ticker | Company |
---|---|
ZVSA | ZyVersa Therapeutics, Inc. |
PDSB | PDS Biotechnology Corporation |
HOOK | HOOKIPA Pharma Inc. |
CRVS | Corvus Pharmaceuticals, Inc. |
INZY | Inozyme Pharma, Inc. |
XFOR | X4 Pharmaceuticals, Inc. |
MREO | Mereo BioPharma Group plc |
CYTO | Altamira Therapeutics Ltd. |
ZURA | Zura Bio Limited |
ELEV | Elevation Oncology, Inc. |
TERN | Terns Pharmaceuticals, Inc. |
OCEA | Ocean Biomedical, Inc. |